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Ceftolozane is a new cephalosporin with activity against Gram-negative and Gram-positive microorganisms. However, the com-
pound is susceptible to degradation by extended-spectrum beta-lactamases (ESBLs). Tazobactam is an ESBL inhibitor and is
combined with ceftolozane to broaden its activity. Surprisingly, although tazobactam has been available for over 20 years, few if
any reliable data exist on the tazobactam pharmacokinetic (PK) properties in mice. To evaluate the PK and pharmacodynamic
(PD) relationships in mice, the PK properties of tazobactam and ceftolozane were extensively investigated. Thigh-infected neu-
tropenic CD-1 mice were injected intraperitoneally with a single 0.1-ml dose containing ceftolozane, tazobactam, or both com-
pounds. Ceftolozane was applied in 2-fold-increasing doses of 4 mg/kg of body weight to 64 mg/kg alone or in combination. Ta-
zobactam was combined in reverse doses (thus, 64/4 mg/kg, 32/8 mg/kg, etc.) (n 2 per time point). In separate validation
experiments, ceftolozane-tazobactam was given alone or in combination at 32/8 mg/kg and 8/32 mg/kg (n 4 per time point).
Plasma samples (one per mouse) and bronchoalveolar lavage samples were collected at up to 12 time points until 6 h after ad-
ministration. There were no significant differences in the ceftolozane and tazobactam PK alone versus combined, indicating no
PK interaction. The PKs were linear and dose proportional for both compounds and showed a good penetration in the epithelial
lining fluid. The estimated mean (standard deviation) half-life of ceftolozane was 0.287 h (0.031 h), and that of tazobactam was
0.176 h (0.026), and the Vwas 0.43 liter/kg and 1.14 liter/kg, respectively. The estimates of tazobactam parameters can also be
used to (re)interpret PD data.
Ceftolozane is a novel cephalosporin with activity against Pseu-domonas aeruginosa and other Gram-negative microorgan-
isms. However, the compound is susceptible to degradation by
extended-spectrum beta-lactamases (ESBLs); therefore, the com-
pound is combined with tazobactam, a potent beta-lactamase in-
hibitor, to broaden its activity. The combination had been shown
to be active in vitro against a wide variety of microorganisms with
different resistance mechanisms (1–5). The combination has also
been shown to be active in vivo, in particular in animal models,
against both P. aeruginosa and Enterobacteriaceae (6, 7). However,
the pharmacodynamics of tazobactam in vivo have not been fully
identified, despite being available for over 20 years in the combi-
nation piperacillin-tazobactam. Indeed few, if any, reliable data
exist on the tazobactam pharmacokinetic (PK) properties in mice,
including its penetration in lung epithelial lining fluid (ELF), pre-
cluding pharmacodynamic analyses. In addition, it is not clear
whether pharmacokinetic interactions exist between cephalospo-
rins and tazobactam. In one earlier, limited study, such a pharma-
cokinetic interaction was observed between these two compounds
(8) in mice, although it was not observed in men (9). Thus, the
primary objectives of this study were to evaluate the pharmacoki-
netic profiling of ceftolozane and tazobactam in the mouse plasma
and ELF and to assess potential drug interactions using a neutro-
penic murine thigh or lung infection model. Additionally, the
protein binding and the pulmonary penetration of both agents
were determined.
MATERIALS AND METHODS
Animals and setting. Outbred female CD-1 mice obtained from Charles
River (The Netherlands) and weighing 18 to 22 g at arrival were used in the
experiments. Mice were rendered neutropenic by intraperitoneal (i.p.)
injections of cyclophosphamide, 150 mg/kg of body weight at day4 and
100 mg/kg at day1 (10). The experiments were carried out in the Cen-
tral Animal Facility (Centraal Dierenlab) at Radboud University Nijme-
gen Medical Centre. The animal studies were conducted in accordance
with the recommendations of the European Community Directive 86/
609/EEC, 24 November 1986. Studies were approved by the animal wel-
fare committee of the Radboud University, no. RU-DEC 2011-102 and
RU-DEC 2012-147.
Drugs. Ceftolozane and tazobactam were supplied by Cubist Pharma-
ceuticals. Drugs were reconstituted in normal sterile saline (0.9% NaCl),
according to the manufacturer’s instructions, to a concentration of 200
mg/ml for ceftolozane and 100 mg/ml for tazobactam. Solutions were
stored at 80°C until use and were combined with and/or diluted in
normal saline to the final concentration needed for the experiments.
Infection and dosing. On the day of the experiment, animals were
infected with an inoculum of approximately 5 106 bacteria (normal or
washed) per thigh, a different strain in each thigh. Klebsiella pneumoniae
ATCC 700603 and a clinical Escherichia coli isolate were used in all exper-
iments. Mice (n  458) were injected i.p. with a 0.1-ml single dose con-
taining ceftolozane, tazobactam, or both compounds combined 2 h after
infection. Ceftolozane was applied in 2-fold increasing doses of 4 mg/kg to
64 mg/kg alone or in combination with tazobactam. Tazobactam was
combined in reverse doses (thus, 64/4 mg/kg, 4/64 mg/kg, 32/8 mg/kg,
and 8/32 mg/kg) (n  2 mice per time point). In separate validation
experiments to show indifference in pharmacokinetic profiling of the
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compounds alone or in combination, as well as to determine the ELF
penetration, ceftolozane and tazobactam were given alone or in combina-
tion at ceftolozane-tazobactam doses of 32/8 mg/kg and 8/32 mg/kg (n
4 mice per time point). For the 32/8-mg/kg dose, a second, separate inoc-
ulum control experiment was performed by washing the inoculum
through centrifugation for 5 min and resuspending it in saline to the
appropriate number of CFU/ml to determine whether free beta-lactamase
in the inoculum has an impact on the pharmacokinetic profile of ceftolo-
zane (11).
Sampling and analysis. Blood samples of at least 0.5 ml for PK anal-
yses were collected in 1-ml K3EDTA tubes through orbital sinus bleeding
under isoflurane sedation following each single dose, just prior to dosing
(hour 0) and at 0.083, 0.167, 0.33, 0.5, 0.75, 1, 1.5, 2, 3, 4, and 6 h after
administration (one sample per mouse). Samples were immediately put
on ice, and the blood subsequently was centrifuged in a precooled centri-
fuge and stored at 80°C until analysis. Bronchoalveolar lavage (BAL)
samples were obtained immediately after mice were killed humanely, sub-
sequent to previous blood collection. The ELF was obtained using a tech-
nique described previously (12). In short, after being killed under isoflu-
rane anesthesia by cervical dislocation, mice were secured on a plastic
platform, and the trachea was exposed by a 1-cm incision on the ventral
neck skin for insertion of the cannula that was sutured in place. Lungs
were instilled 4 times with 0.5 ml of sterile 0.9% saline, and the fluid was
aspirated immediately. The aspirates thus recovered were pooled, directly
placed on ice, and subsequently stored at80°C.
Concentrations of ceftolozane and tazobactam in the ELF were deter-
mined by using the ratio of the urea concentration in the BAL fluid to that
in the plasma, as measured with a modified enzymatic assay (Quanti-
Chrom urea assay kit, DIUR-500; BioAssay Systems). The standard
curve was linear, with a detection limit from 0.08 mg/dl to 100 mg/dl.
Protein binding in plasma was determined by the ultrafiltration tech-
nique. To obtain enough volume, plasma samples were pooled to obtain a
concentration range of 2 to 35 mg/liter for ceftolozane and 0.1 to 7 mg/
liter for tazobactam.
Concentrations were determined in plasma as well as in the ultrafil-
trate. The ultrafiltrate was obtained using a Centrifree cartridge (30,000
MWCO; Millipore) and centrifuging at 1,300  g for 15 min. During
validation of the drug assessment protocol, no drug was lost during ultra-
filtration due to nonspecific binding to components of the Centrifree
device. The quantitative analysis of the ceftolozane and tazobactam con-
centrations in the blood and ELF was performed in a separate facility
(MicroConstants, Inc., San Diego, CA). Briefly, samples containing cef-
tolozane and tazobactam, with FR259647 (Calixa Therapeutics, Inc.) and
sulbactam as their respective internal standards and sodium heparin as the
anticoagulant, were precipitated with a methanol-acetonitrile solution.
The supernatant was further diluted as appropriate, and the sample ex-
tract was divided for analysis on two separate liquid chromatography-
tandem mass spectrometry (LC/MS) systems. Ceftolozane was analyzed
using electrospray positive ionization on a Supelco Discovery HS F5 col-
umn. Tazobactam was analyzed using electrospray negative ionization
and was further prepared by online solid-phase extraction coupled to a
Thermo Prism RP column. The coefficient of variation (CV) for the cef-
tolozane and tazobactam quality control samples ranged from 4.92% to
6.42% and 4.64% to 13.3%, respectively. The limit of detection for cef-
tolozane was 0.1 mg/liter and was 0.02 mg/liter for tazobactam.
Pharmacokinetic analysis. The PK analysis was performed using
noncompartmental modeling in GraphPad Prism 5.0 and WinNonlin 2.1
(Pharsight Corp., St. Louis, MO). The area under the concentration-time
curve (AUC) was measured using the log-linear trapezoidal rule from the
pooled data set for each curve (n  2 or n  4 per data point). The
penetration in ELF was calculated as the AUC in the ELF divided by that in
the plasma. Dose proportionality was determined following the standard
methods by determining the relationship between the log(dose) and the
log(AUC) following the power model approach (13).
RESULTS
Concentrations in plasma.Figure 1 (left panel) shows an example
of the concentration-time curve of ceftolozane for the 32-mg/kg
dose with the pooled data. Likewise, Fig. 1 (right panel) shows an
example of the concentration-time curve of tazobactam for the
8-mg/kg dose. There was a fast absorption phase and subsequent
elimination for both compounds. The pharmacokinetics of both
compounds in the plasma appears to be linear and dose propor-
tional, as demonstrated by the dose proportionality in the plasma,
as shown in Fig. 2. For ceftolozane (Fig. 2, left panel), the regres-
sion line for dose proportionality is shown both with and without
tazobactam. There appears to be no significant difference between
the two lines (P  0.50). The overall pooled relationship can be
described by log(AUC) 0.208 0.742 log(dose ceftolozane).
Only two concentration-time curves were performed for tazobac-
tam without ceftolozane; therefore, these are displayed as dots
only (Fig. 2, right panel). The relationship of tazobactam with
ceftolozane can be described by log(AUC)  0.865  1.156 
log(dose tazobactam). Table 1 shows the pharmacokinetic profil-
ing of ceftolozane and tazobactam. There was no significant dif-
ference in clearance (P 0.99), half-life (P 0.1), or V (P 0.13)
of ceftolozane with or without tazobactam. There was no clear
effect observed of washing the inoculum.
Protein binding. Protein binding was performed on pooled
samples at concentrations ranging from 2 to 35 mg/liter for cef-
tolozane and 0.1 to 7 mg/liter for tazobactam. The overall esti-
mates were 5.1% (standard error [SE], 0.85%; n 10) for ceftolo-
zane and 25.1% (SE, 2.45%; n  14) for tazobactam. There
appeared to be no concentration-dependent protein binding over
the concentration range measured.
Concentrations in ELF. Figure 1 shows examples of the con-
centration-time profiles of ceftolozane and tazobactam in the ELF
FIG 1 Concentration-time profiles in plasma and epithelial lining fluid (ELF) of neutropenic mice after a 32-mg/kg ceftolozane dose (left panel; n 12 per time
point) or an 8-mg/kg tazobactam dose (right panel; n 10 or 12 per time point). Error bars indicate the standard error of the mean (SEM) (for some data points
overlapping with the symbol).
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together with the plasma for the two doses studied. Like in the
plasma, the concentrations at the last time point may have been
slightly overestimated, because a limited number of samples had
concentrations below the lower limit of quantification (LLQ).
However, this did not affect the pharmacokinetic parameter esti-
mates.
Table 2 shows the penetration of ceftolozane and tazobactam
in the ELF for the two different doses. Both compounds followed
the concentrations in plasma and appeared to penetrate well in the
ELF. For unbound concentrations (in ELF and plasma), the mean
penetration ratio was 0.33 for ceftolozane and was 0.77 for tazo-
bactam.
DISCUSSION
In this study, we found that the pharmacokinetics of both tazo-
bactam and ceftolozane were linear over a range of doses from 4 to
64 mg/kg. The half-life of tazobactam was approximately 10 min.
We found no earlier reference to tazobactam pharmacokinetics in
mice, except for the studies by Fournier et al. (14) and Bulik et al.
(8). However, in the study by Fournier et al., no specific pharma-
cokinetic data are provided other than a concentration-time plot;
in the study by Bulik et al., the authors simulated human pharma-
cokinetics in their specific model, so the results cannot be directly
compared. In the current study, i.p. injections were utilized, while
most previous in vivo studies used subcutaneous doses. Of note,
we did not find any pharmacokinetic interaction between tazo-
bactam and ceftolozane, as was alluded to in the preliminary study
by Bulik et al. (8). One possible reason might be that the doses
used in our study were low enough not to show any; in the study by
Bulik et al., the dosing regimens were adjusted by lowering the
dose but giving doses more often to account for drug interactions.
In humans, such a drug interaction is not observed (9).
The pharmacokinetics of ceftolozane were in agreement with
that found by Craig and Andes (15) using a biological assay (single
doses of 25, 100, and 400 mg/kg), although the half-life we found
was slightly longer (17 min versus 12 to 14 min). In their discus-
sion, the authors note that the half-life they found in their studies
may have been too short due to the use of a bioassay, which
thereby explained the relatively short percent free time above the
MIC found for stasis in their mouse model. Our results show a
slightly longer half-life, but this does not fully explain that result.
The protein binding values were also comparable. Overall, the two
studies provide a good framework for ceftolozane plasma phar-
macokinetics in mice.
Both ceftolozane and tazobactam were found to penetrate well
in the ELF. Although we used a thigh infection model, we think
that a lung infection will not alter ELF penetrations, since these
were independent to the infection model for ceftazidime and
avibactam in another study by our group (13). Recently, ceftolo-
zane penetration was described in human ELF as being 48% (16)
for the total drug and 59% for the unbound fraction. The authors
assumed a protein binding of 20% for ceftolozane in humans,
which is higher than in mice. The penetration we found for cef-
tolozane in mice was lower, but it was slightly higher than the
penetration of ceftazidime found in the same model (13). We do
not have a clear explanation for the slightly higher penetration of
ceftolozane compared to ceftazidime. Tazobactam penetration in
the ELF was significantly higher than that of ceftolozane; after
correction for protein binding, penetration exceeded 70% on av-
erage, which is a promising result to further investigate the phar-
macodynamics of tazobactam combined with a beta-lactam com-
pound. It was also much higher than the avibactam penetration in
the ELF of 27% found in one of our other studies, using the same
murine models (13). The penetration ratio of tazobactam in hu-
mans was described as 0.49 for the total drug and, when corrected
FIG 2 Dose proportionality of ceftolozane (left panel) and tazobactam (right panel) in plasma of infected mice after single doses. AUC, area under the
concentration-time curve; dose, a single dose, administered intraperitoneally.
TABLE 1 Pharmacokinetic parameter estimates of ceftolozane and tazobactam in thigh-infected neutropenic mice
Drug No. of curvesa
Pharmacokinetic parametersb
CL (liter/h/kg) t1/2 (min) V (liter/kg)
Estimate SD Estimate SD Estimate SD
Ceftolozane (overall) 15 1.33 0.32 17.2 1.86 0.43 0.15
Without tazobactam 7 1.32 0.38 18.1 2.36 0.47 0.18
With tazobactam 8 1.33 0.29 16.5 0.80 0.39 0.10
Tazobactam 10 4.64 1.46 10.6 1.57 1.14 0.56
a Drug doses of 4 to 64 mg/kg.
b CL, clearance; t1/2, half-life; V, volume of distribution.
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for protein binding, was comparable to our results. Fournier et al.
(14) looked at tazobactam concentrations in lung homogenates
and concluded that tazobactam penetrated well and appeared to
be dose dependent. However, interpretations of such studies
should be viewed with great caution (17), because, by grinding up
tissue consisting of distinct compartments in which the drug is not
necessarily distributed in an homogeneous fashion or available for
activity, this method may result in underestimation or overesti-
mation of the drug levels on the side infection.
We conclude that both ceftolozane and tazobactam display
linear pharmacokinetics in mice and show a good penetration in
ELF. Additionally, similar to that seen in humans, we did not
detect an interaction between ceftolozane and tazobactam in our
murine model.
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Ceftolozane 8 6.86 2.20 0.32 0.34
32 21.64 6.42 0.30 0.31
Tazobactam 8 2.05 0.91 0.45 0.60
32 7.25 4.51 0.62 0.83
a Free-drug ELF/free-drug plasma.
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